CD274 and non-small cell lung carcinoma: In combined analysis of the cohorts A and C, there was a significant interaction between ALI and the type of treatment (for ICI versus chemotherapy, HR = 0.69 with P = 0.0009; for ALI >18 versus ALI ≤18, HR = 0.71 with P = 0.0006; for the interaction between ALI and the type of treatment, HR = 0.55 with P = 0.0004), suggesting that the ALI is both prognostic for NSCLC patients, and predictive for the benefit from PD-L1 inhibitor monotherapy.